Marshall Wace LLP Decreases Stake in Anika Therapeutics, Inc. (NASDAQ:ANIK)

Marshall Wace LLP lessened its position in shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) by 18.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,814 shares of the biotechnology company’s stock after selling 6,478 shares during the quarter. Marshall Wace LLP owned about 0.19% of Anika Therapeutics worth $705,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Lazard Asset Management LLC bought a new position in shares of Anika Therapeutics in the 1st quarter valued at about $180,000. State Board of Administration of Florida Retirement System bought a new stake in shares of Anika Therapeutics in the 1st quarter valued at approximately $198,000. SG Americas Securities LLC boosted its holdings in shares of Anika Therapeutics by 7.8% in the 1st quarter. SG Americas Securities LLC now owns 8,615 shares of the biotechnology company’s stock worth $219,000 after purchasing an additional 627 shares during the period. BNP Paribas Financial Markets increased its position in shares of Anika Therapeutics by 16.9% during the 1st quarter. BNP Paribas Financial Markets now owns 22,240 shares of the biotechnology company’s stock valued at $565,000 after purchasing an additional 3,217 shares during the last quarter. Finally, American Century Companies Inc. raised its holdings in Anika Therapeutics by 11.8% during the 2nd quarter. American Century Companies Inc. now owns 23,892 shares of the biotechnology company’s stock valued at $605,000 after buying an additional 2,518 shares during the period. Institutional investors own 91.53% of the company’s stock.

Anika Therapeutics Price Performance

Shares of NASDAQ ANIK opened at $24.64 on Wednesday. Anika Therapeutics, Inc. has a 1 year low of $17.88 and a 1 year high of $29.11. The firm has a 50-day simple moving average of $25.30 and a two-hundred day simple moving average of $25.84. The company has a market cap of $359.42 million, a P/E ratio of -4.69 and a beta of 0.83.

Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.24). The business had revenue of $41.92 million for the quarter, compared to the consensus estimate of $39.90 million. Anika Therapeutics had a positive return on equity of 0.94% and a negative net margin of 44.45%. During the same period in the prior year, the business posted ($0.06) earnings per share. As a group, equities research analysts expect that Anika Therapeutics, Inc. will post -0.1 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Barrington Research reaffirmed an “outperform” rating and set a $37.00 price objective on shares of Anika Therapeutics in a research note on Friday, August 9th.

Anika Therapeutics Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.